TGA updates
What the TGA changed, and what it means for you.
Every update from the Therapeutic Goods Administration that affects your brand, with a plain note from us on what to do. Updated as the TGA publishes.
Update to listed medicine ingredients in October 2026
Listed medicine ingredients and requirements for their use have been updated in the Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2026.
Read the TGA update →Andrographis recalls: Concerns over allergy risk
Consumers are advised that the medicines listed below containing Andrographis paniculata (Andrographis) are being recalled due to the risk of severe allergic reactions.
Read the TGA update →Consent relating to listed medicines that contain whole live microorganisms as an active ingredient
This consent is given under sections 14 and 14A of the Therapeutic Goods Act 1989.
Read the TGA update →Listed Medicine Compliance Reports - September 2026 update
We've updated the Listed Medicine Compliance Reports database with the results of compliance reviews covering 7 listed medicines.
Read the TGA update →TGA releases new guidance to explain when news content may be advertising
We have published new guidance to help journalists and news organisations understand when media reporting on therapeutic goods may be regulated as advertising.
Read the TGA update →New medicine labelling standards
New medicine labelling standards have been published to replace TGO 91 and TGO 92. Sponsors will have a 5-year transition period to update labels.
Read the TGA update →Determining when news is subject to the therapeutic goods advertising rules
This guidance is for journalists and news organisations and explains when news reports about therapeutic goods may be regulated as advertising.
Read the TGA update →Andrographis removed from listed medicines framework because of allergy risk
Andrographis paniculata (Andrographis) has been removed from the ingredients allowed in new listed medicines intended for supply in Australia from 17 September 2026.
Read the TGA update →High-moderate risk changes to permissible ingredients - Andrographis paniculata 2026
We have decided to remove Andrographis paniculata from the Permissible Ingredients Determination following an updated safety review and supplementary report and consideration of submissions received through a targeted consultation.
Read the TGA update →Applying the Advertising Code rules: prominently displayed or communicated information
This guidance explains parts 4 and 5 of the Code, which requires certain information to be prominently displayed or communicated in advertisements for therapeutic goods.
Read the TGA update →TGA tests counterfeit retatrutide product following serious adverse event report
Retatrutide products marketed for weight loss may pose a serious risk to your health and should not be used.
Read the TGA update →Nutra-life Magnesium and Sleep Products and Musashi Pre Workout Chewables
Vitaco Health Australia Pty Ltd (Vitaco) is alerting customers that sucralose, an artificial sweetener, was used in 23 batches of Nutra-life and Musashi products rather than thaumatin, a natural sweetener.
Read the TGA update →CAROTONE skin-brightening products found to contain undeclared prescription-only medicine
We are advising consumers that CAROTONE products marketed for skin brightening may pose a serious risk to your health and should not be used.
Read the TGA update →Melanotan II tanning peptide products found to be inconsistently dosed
TGA is warning consumers against using Melanotan II tanning products.
Read the TGA update →Understanding the legislative framework for listed medicines
Guidance providing an overview of the legislative framework for listed medicines and assessed listed medicines.
Read the TGA update →Making NAD, NAD+, NADH or NMN representations for listed medicines
This guidance is to assist sponsors in fulfilling the regulatory obligations necessary to ensure that any representations made about their listed medicine(s) comply with the requirements of the Therapeutic Goods Act 1989.
Read the TGA update →GLP-1 RAs and rare, but severe, eye disorders
Product warnings across the GLP-1 RA class of medicines have been updated due to the potential for these products to cause a rare, but severe, form of eye disorder.
Read the TGA update →Advertising to health professionals so that consumer rules do not apply
Guidance about how to advertise therapeutic goods exclusively to health professionals.
Read the TGA update →Stay Plumb
Get the updates that matter to your range.
Stay Plumb clients get these checked against their own products, with a note when something needs action.
One email when the rules move.
The updates that affect your brand, with our note on each. No marketing.